MetaVia (NASDAQ:MTVA) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of MetaVia (NASDAQ:MTVA) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Other analysts have also issued research reports about the company. HC Wainwright increased their price objective on MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.50.

MetaVia Stock Down 4.9%

NASDAQ MTVA opened at $2.31 on Friday. The company has a 50-day simple moving average of $7.00 and a two-hundred day simple moving average of $8.33. MetaVia has a 12-month low of $2.26 and a 12-month high of $23.10. The firm has a market cap of $5.08 million, a price-to-earnings ratio of -0.28 and a beta of 0.28.

MetaVia (NASDAQ:MTVA) last released its earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.86) by $1.32. Equities analysts expect that MetaVia will post -3.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new position in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.